Neurocrine Biosciences
NBIX
#1518
Rank
NZ$19.75 B
Marketcap
$198.14
Share price
-0.48%
Change (1 day)
-13.85%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

EPS for Neurocrine Biosciences (NBIX)

EPS in 2023 (TTM): $3.22

According to Neurocrine Biosciences 's latest financial reports the company's current EPS (TTM) is $3.42. In 2022 the company made an earnings per share (EPS) of $2.81 an increase over its 2021 EPS that were of $1.66.

EPS history for Neurocrine Biosciences from 1997 to 2023

Annual EPS

Year EPS Change
2023 (TTM)$3.2214.59%
2022$2.8169.47%
2021$1.66-78.21%
2020$7.61990%
2019$0.7081.82%
2018$0.38-113.5%
2017-$2.850.62%
2016-$2.8357.28%
2015-$1.8025.61%
2014-$1.4318.84%
2013-$1.21-1085.71%
2012$0.12-89.71%
2011$1.19-500%
2010-$0.30-86.92%
2009-$2.27-43.48%
2008-$4.02-57.8%
2007-$9.5292.58%
2006-$4.94371.67%
2005-$1.05-52.76%
2004-$2.2236.56%
2003-$1.62-70%
2002-$5.41118.31%
2001-$2.488.4%
2000-$2.2948.86%
1999-$1.54-20%
1998-$1.92-479.31%
1997$0.51

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
$3.65 6.63%๐Ÿ‡บ๐Ÿ‡ธ USA
$0.96-71.94%๐Ÿ‡ฌ๐Ÿ‡ง UK
-$5.17-251.02%๐Ÿ‡บ๐Ÿ‡ธ USA
$9.48 177.00%๐Ÿ‡บ๐Ÿ‡ธ USA
$6.43 87.79%๐Ÿ‡บ๐Ÿ‡ธ USA
$3.25-5.10%๐Ÿ‡บ๐Ÿ‡ธ USA
-$0.82-123.98%๐Ÿ‡บ๐Ÿ‡ธ USA
-$5.29-254.59%๐Ÿ‡บ๐Ÿ‡ธ USA